Home > Healthcare > Medical Devices > Diagnostic Devices > Cardiac Biomarkers Market
Cardiac Biomarkers Market Size
- Report ID: GMI7121
- Published Date: Oct 2023
- Report Format: PDF
Cardiac Biomarkers Market Size
Cardiac Biomarkers Market size was valued at USD 9.4 billion in 2022 and is estimated to account for USD 31.2 billion by 2032. Cardiac biomarkers are substances or molecules that are measured in the blood to assess the health and function of the heart.
These biomarkers serve as diagnostic tools to detect and evaluate various cardiac conditions, including heart attack, failure, and other such disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the primary cause of global mortality, responsible for an estimated 18 million deaths each year.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Cardiac Biomarkers Market Size in 2022: | USD 9.4 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR: | 12.8% |
| 2032 Value Projection: | USD 31.2 Billion |
| Historical Data for: | 2018 to 2022 |
| No. of Pages: | 118 |
| Tables, Charts & Figures: | 223 |
| Segments covered: | Product, Application, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Increasing prevalence of CVDs is likely to increase the demand for cardiac markers. As the number of individuals affected by CVDs increases, there will be a greater need for diagnostic tools and biomarkers to identify, assess, and manage these conditions. As people become more informed about the risk factors for CVDs, including high blood pressure, high cholesterol, obesity, smoking, and physical inactivity, they are increasingly motivated to monitor their heart health.
Frequently Asked Questions (FAQ) :
Cardiac Biomarkers Market Scope
